Endoscopy and Primary Sclerosing Cholangitis

Brief summary (registry, in English)

Primary Sclerosing Cholangitis (PSC) is a chronic, cholestatic, immune-mediated liver disease characterized by segmental inflammation, fibrosis and destruction of the intra and / or extrahepatic biliary tree. Patients suffering from PSC can develop biliary strictures and symptoms (jaundice, itching, cholangitis) requiring endoscopic therapy by Endoscopic Retrograde Cholangiopancreatography (ERCP). ERCP can play an important role in symptoms control, cholangiocarcinoma diagnosis. PSC can lead to liver failure and subsequent need for liver transplantation, ERCP can therefore delay the time for liver transplantation. With this work the investigators want to report our thirty years of experience in the endoscopic treatment of PSC.

What you commit to

• Study type: Observational
• Participants enrolled: 118
• From 1 Jul 2021 to the primary completion date, 4 Nov 2024
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.